Literature DB >> 3302285

The treatment of alcoholic methadone patients: a review.

W K Bickel, I Marion, J H Lowinson.   

Abstract

Alcoholism is a major problem among methadone maintenance patients. Although alcoholism in the methadone patient is recognized as a problem, few treatment studies have been conducted. Treatment studies have examined abstinence oriented and controlled drinking therapies, voluntary disulfiram treatment, and combined behavioral-pharmacological treatment. The first three treatments were shown to be ineffective in impacting alcohol consumption. The ineffectiveness reported by these studies was attributed to patients' lack of motivation. However, the combined behavioral-pharmacological treatment, which made methadone treatment contingent on antabuse consumption, resulted in decreases in both alcohol consumption and arrests, with increases occurring in employment. Future research should examine the generality of the findings from combined treatment as well as examine whether other contingency management procedures may reduce alcohol consumption in the alcoholic methadone patient.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3302285     DOI: 10.1016/0740-5472(87)90005-5

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  12 in total

Review 1.  Referral and screening for substance abuse treatment in jails.

Authors:  R H Peters
Journal:  J Ment Health Adm       Date:  1992

2.  Problem drinking and low-dose naltrexone-assisted opioid detoxification.

Authors:  Paolo Mannelli; Kathleen Peindl; Ashwin A Patkar; Li-Tzy Wu; Haresh M Tharwani; David A Gorelick
Journal:  J Stud Alcohol Drugs       Date:  2011-05       Impact factor: 2.582

Review 3.  Methadone maintenance in the treatment of opioid dependence. A current perspective.

Authors:  J E Zweben; J T Payte
Journal:  West J Med       Date:  1990-05

4.  Prevalence of Heavy Alcohol Use Among People Receiving Methadone Following Change to Methadose.

Authors:  Jan Klimas; Evan Wood; Ekaterina Nosova; M-J Milloy; Thomas Kerr; Kanna Hayashi
Journal:  Subst Use Misuse       Date:  2017-06-12       Impact factor: 2.164

5.  Real-time assessment of alcohol drinking and drug use in opioid-dependent polydrug users.

Authors:  Kenzie L Preston; Michelle L Jobes; Karran A Phillips; David H Epstein
Journal:  Behav Pharmacol       Date:  2016-10       Impact factor: 2.293

6.  Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.

Authors:  Roberto Ciccocioppo; Daina Economidou; Roberto Rimondini; Wolfgang Sommer; Maurizio Massi; Markus Heilig
Journal:  Biol Psychiatry       Date:  2006-03-14       Impact factor: 13.382

7.  Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.

Authors:  John D Roache; Martina Pavlicova; Aimee Campbell; Tse-Hwei Choo; Michelle Peavy; Andrea S Kermack; Edward V Nunes; John Rotrosen
Journal:  Alcohol Clin Exp Res       Date:  2021-11-23       Impact factor: 3.455

8.  Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users.

Authors:  Jan Klimas; Christopher Fairgrieve; Helen Tobin; Catherine-Anne Field; Clodagh Sm O'Gorman; Liam G Glynn; Eamon Keenan; Jean Saunders; Gerard Bury; Colum Dunne; Walter Cullen
Journal:  Cochrane Database Syst Rev       Date:  2018-12-05

Review 9.  Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users: Cochrane Review.

Authors:  Jan Klimas; Catherine-Anne Field; Walter Cullen; Clodagh Sm O'Gorman; Liam G Glynn; Eamon Keenan; Jean Saunders; Gerard Bury; Colum Dunne
Journal:  Syst Rev       Date:  2013-01-12

10.  Problem alcohol use among problem drug users in primary care: a qualitative study of what patients think about screening and treatment.

Authors:  Catherine Anne Field; Jan Klimas; Joseph Barry; Gerard Bury; Eamon Keenan; Bobby P Smyth; Walter Cullen
Journal:  BMC Fam Pract       Date:  2013-07-13       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.